MONJUVI + Rituximab & Lenalidomide: The First and Only CD19- and CD20-targeted Immunotherapy Combination Approved for 2L+ Follicular Lymphoma Patients

Event Date:

Sep 17, 2025

Credit Type:

--

Credits:

--